Obviousness and Pharmaceutical Method of Treatment Claims
Patently O
APRIL 1, 2024
by Dennis Crouch In April 2024, the Federal Circuit issued a significant decision vacating a district court’s judgment that Janssen Pharmaceuticals’ dosing regimen patent claims were nonobvious. The case involved Janson’s U.S. Janssen Pharms., Teva Pharms. USA, Inc. , 2022-1258 (Fed.
40 
Let's personalize your content